[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"49601ae5-fd50-4ceb-b7f3-e357f9864917","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922724","created_at":"2021-01-18T19:17:55.581Z","updated_at":"2025-02-25T12:27:11.116Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03922724","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • HLA-B • HLA-C","pipe":" | ","alterations":" ALK positive","tags":["ALK • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • sirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-24"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"2d8fede0-d3af-4a3f-8d61-856862f007e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128034","created_at":"2021-01-18T15:24:33.202Z","updated_at":"2025-02-25T16:31:10.471Z","phase":"Phase 1/2","brief_title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","source_id_and_acronym":"NCT03128034","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/24/2017","start_date":" 10/24/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2025-02-07"},{"id":"e7c4a744-912a-46be-99ad-d7bc540b1466","acronym":"","url":"https://clinicaltrials.gov/study/NCT04177004","created_at":"2021-01-18T20:22:19.514Z","updated_at":"2025-02-25T16:37:37.764Z","phase":"Phase 1","brief_title":"Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant","source_id_and_acronym":"NCT04177004","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 10/27/2025","primary_completion_date":" 10/27/2025","study_txt":" Completion: 10/27/2025","study_completion_date":" 10/27/2025","last_update_posted":"2025-02-06"},{"id":"7c4709ee-03b2-4e5b-b8af-61df0f32ed05","acronym":"NCI-2018-01788","url":"https://clinicaltrials.gov/study/NCT03670966","created_at":"2021-01-18T18:00:29.277Z","updated_at":"2025-02-25T16:44:27.913Z","phase":"Phase 1/2","brief_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03670966 - NCI-2018-01788","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 06/28/2027","primary_completion_date":" 06/28/2027","study_txt":" Completion: 03/20/2029","study_completion_date":" 03/20/2029","last_update_posted":"2025-02-05"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"ec81dee1-ccab-428c-9718-7a66b69c4ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT06743503","created_at":"2025-02-26T07:40:37.187Z","updated_at":"2025-02-26T07:40:37.187Z","phase":"Phase 1","brief_title":"UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies","source_id_and_acronym":"NCT06743503","lead_sponsor":"Nanjing IASO Biotechnology Co., Ltd.","biomarkers":" CD20 • CD8 • CD4 • NCAM1 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD4 • NCAM1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/31/2024","start_date":" 12/31/2024","primary_txt":" Primary completion: 05/21/2028","primary_completion_date":" 05/21/2028","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2024-12-20"},{"id":"4574703b-19bd-4bd3-9dd9-9adace3f6487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896839","created_at":"2023-06-09T16:06:51.642Z","updated_at":"2024-07-02T16:34:27.634Z","phase":"Phase 1/2","brief_title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","source_id_and_acronym":"NCT05896839","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/11/2024","start_date":" 08/11/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"68d8ce34-194a-45f2-9e93-7c94e62c1815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02356159","created_at":"2021-01-18T11:12:44.041Z","updated_at":"2024-07-02T16:34:36.807Z","phase":"Phase 1/2","brief_title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT02356159","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/24/2015","start_date":" 09/24/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-10"},{"id":"1782eac1-bff9-41f2-9bc7-5e0ddfcda445","acronym":"","url":"https://clinicaltrials.gov/study/NCT06437574","created_at":"2024-05-31T20:35:39.012Z","updated_at":"2024-07-02T16:34:37.911Z","phase":"Phase 2","brief_title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","source_id_and_acronym":"NCT06437574","lead_sponsor":"Cedars-Sinai Medical Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • ezetimibe/simvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-06-05"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"86dc7e81-ec59-452b-a3ee-1c37d19391d6","acronym":"NCI-2019-03188","url":"https://clinicaltrials.gov/study/NCT03970096","created_at":"2021-01-18T19:31:38.073Z","updated_at":"2024-07-02T16:35:00.086Z","phase":"Phase 2","brief_title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03970096 - NCI-2019-03188","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-05-30"},{"id":"2389ac55-3a18-481d-8919-40b11f2cb668","acronym":"NCI-2017-01069","url":"https://clinicaltrials.gov/study/NCT03192397","created_at":"2021-01-18T15:44:50.740Z","updated_at":"2024-07-02T16:35:00.229Z","phase":"Phase 1/2","brief_title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT03192397 - NCI-2017-01069","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/21/2027","study_completion_date":" 05/21/2027","last_update_posted":"2024-05-29"},{"id":"d888b6c9-4b44-4498-aef7-22dac96f744f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163357","created_at":"2021-01-18T04:38:10.114Z","updated_at":"2024-07-02T16:35:00.426Z","phase":"Phase 1","brief_title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","source_id_and_acronym":"NCT01163357","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/28/2011","start_date":" 01/28/2011","primary_txt":" Primary completion: 07/20/2019","primary_completion_date":" 07/20/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"2e6bf495-dfa3-4ba8-b86c-4970f2d282c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01428973","created_at":"2021-01-18T05:54:04.661Z","updated_at":"2024-07-02T16:35:04.762Z","phase":"Phase 2","brief_title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","source_id_and_acronym":"NCT01428973","lead_sponsor":"University of Liege","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"cfd16a88-a21f-4f4a-9eae-003d4305ffa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05120570","created_at":"2021-11-15T12:53:40.169Z","updated_at":"2024-07-02T16:35:08.491Z","phase":"Phase 1/2","brief_title":"PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation","source_id_and_acronym":"NCT05120570","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • VIC-1911"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-04-22"},{"id":"58325824-732c-4519-aaf2-9bb65afc637a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00544115","created_at":"2021-01-18T01:58:43.943Z","updated_at":"2024-07-02T16:35:11.891Z","phase":"Phase 2","brief_title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","source_id_and_acronym":"NCT00544115","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan • cyclosporine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 10/16/2001","start_date":" 10/16/2001","primary_txt":" Primary completion: 03/13/2007","primary_completion_date":" 03/13/2007","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-02"},{"id":"9b0dc769-7e69-4597-ba4b-209925af9306","acronym":"","url":"https://clinicaltrials.gov/study/NCT02891603","created_at":"2021-01-18T14:11:34.890Z","updated_at":"2024-07-02T16:35:12.946Z","phase":"Phase 1/2","brief_title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","source_id_and_acronym":"NCT02891603","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 04/18/2022","study_completion_date":" 04/18/2022","last_update_posted":"2024-03-25"},{"id":"4211f101-f1d0-468e-8f27-160ea15704ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01885689","created_at":"2022-01-21T21:57:48.003Z","updated_at":"2024-07-02T16:35:14.418Z","phase":"Phase 2","brief_title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT01885689","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • clofarabine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/10/2014","start_date":" 02/10/2014","primary_txt":" Primary completion: 12/27/2019","primary_completion_date":" 12/27/2019","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-15"},{"id":"be1b1cbc-6baf-4848-9f92-082e2b4cd6b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01203722","created_at":"2021-01-18T04:49:23.205Z","updated_at":"2024-07-02T16:35:15.050Z","phase":"Phase 1/2","brief_title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","source_id_and_acronym":"NCT01203722","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-13"}]